BIO-TECHNE Corp — Director's Dealing 2021

Nov 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-10-28

Reporting Person: Nusse Roeland (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-28	Common Stock	A	194	—	Acquired	6959	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-28	Stock Option (right to buy)	$515.24	A	633	Acquired	2031-10-28	Common Stock (633)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$87.39	2023-10-30	Common Stock (4000)	4000	Direct
Stock Option (right to buy)	$91.78	2024-10-30	Common Stock (4000)	4000	Direct
Stock Option (right to buy)	$87.34	2025-10-28	Common Stock (4260)	4260	Direct
Stock Option (right to buy)	$101.19	2026-10-27	Common Stock (3985)	3985	Direct
Stock Option (right to buy)	$125.05	2027-10-26	Common Stock (3125)	3125	Direct
Stock Option (right to buy)	$179.84	2028-10-25	Common Stock (1898)	1898	Direct
Stock Option (right to buy)	$201.64	2029-10-24	Common Stock (2011)	2011	Direct
Stock Option (right to buy)	$255.69	2030-10-29	Common Stock (1507)	1507	Direct

Footnotes

F1: The option vests on the earlier of the one year anniversary of the grant date (10/28/2021) or the date of Bio-Techne's 2022 annual meeting of shareholders.